ClinicalTrials.gg
CompletedNCT02940860Updated Oct 6, 2020Results posted

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

A Phase 3 interventional study of Iron isomaltoside/ferric derisomaltose and Iron sucrose in Iron Deficiency Anaemia, Iron Deficiency Anemia and Chronic Kidney Disease, sponsored by Pharmacosmos A/S. Completed at 141 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,538
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
2nd of 32
1,538 · median 121
Started
2016
with 3 others
Phase 3
18 of 32
4 open now
Registered
8th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 2nd largest by enrollment, is one of 4 that started in 2016, is one of 18 in phase 3, and was the 8th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).

Read the detailed description

Iron deficiency anaemia (IDA) is a common problem associated with many chronic diseases such as chronic kidney disease (CKD). IDA can have a substantial medical and quality of life (QoL) burden on the subjects. Therapy of these subjects includes treating the underlying cause of IDA and restoring haemoglobin (Hb) concentration and iron stores.

This study evaluated the safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).

The study subjects received either a single intravenous (IV) dose of iron isomaltoside/ferric derisomaltose (1000 mg at baseline) or iron sucrose (200 mg IV injections at baseline and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline; a cumulative dose of 1000 mg was recommended). The study subjects were monitored for up to 8 weeks from baseline.

03

Conditions studied

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia
  • Chronic Kidney Disease

Keywords

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia
  • IDA
  • Chronic Kidney Disease
  • CKD
  • Iron isomaltoside
  • Ferric derisomaltose
  • Monofer
  • Monoferric
  • Monover
  • Monofar
  • Monoferro
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women, ≥ 18 years
  2. ≤ 11 g/dL
  3. Chronic renal impairment, as defined by either (i) \< 60 mL/min/1.73m2 at screening (as calculated by modification of diet in renal disease (MDRD)), or (ii) Estimated Glomerular Filtration Rate (eGFR) \< 90 mL/min/1.73m2 at screening and kidney damage as indicated by abnormalities in urine composition per medical history and/or intermediate/high risk of cardio-vascular disease based on the Framingham model
  4. Screening s-ferritin ≤ 100 ng/mL, or ≤ 300 ng/mL if Transferrin Saturation (TSAT) ≤ 30 %
  5. Either no Erythropoiesis Stimulating Agent (ESAs) or ESAs as a stable dose 4 weeks before randomisation
  6. Willingness to participate and signing the form

Exclusion criteria

Exclusion Criteria includes:

  1. Anaemia predominantly caused by factors other than IDA
  2. Hemochromatosis or other iron storage disorders
  3. Previous serious reactions to any IV iron compounds
  4. Prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy
  5. Undergoing dialysis for treatment of CKD
  6. Planned surgical procedure within the trial period
  7. Decompensated liver cirrhosis or active hepatitis
  8. Alcohol or drug abuse within the past 6 month.
  9. Pregnant or nursing women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,538 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside/ferric derisomaltose

    Administered IV

    Drug: Iron isomaltoside/ferric derisomaltose

  • Active comparator
    Iron sucrose

    Administered IV

    Drug: Iron sucrose

Interventions

  • DrugIron isomaltoside/ferric derisomaltose

    Drug page: Iron isomaltoside 1000

    Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.

    Also known as: Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®

  • Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.

    Also known as: Venofer®

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin (Hb) From Baseline to Week 8

    Efficacy Evaluate the effect of iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA). Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with NDD-CKD and IDA, when oral iron preparations were ineffective or could not be used, or in whom the Hb measurement at screening in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.

    Time frame: Baseline to week 8

  2. Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

    Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.

    Time frame: Baseline to week 8

Secondary outcomes

  1. Composite Cardiovascular Adverse Events (AEs)

    Safety Results show the composite cardiovascular AEs, that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.

    Time frame: Baseline, week 1, 2, and 8

  2. Time to First Composite Cardiovascular Safety AE

    Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.

    Time frame: Baseline, week 1, 2, 4, and 8

  3. S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8

    Safety Results show the number of participants who had s-phosphate \<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.

    Time frame: Baseline, week 1, 2, 4, and 8

  4. Hb Concentration Increase of ≥1 g/dL From Baseline to Week 1, 2, 4, and 8

    Efficacy Results show Hb responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 1 g/dL from baseline to the week in question was observed (from baseline to week 1, 2, 4, and 8).

    Time frame: Baseline, week 1, 2, 4, and 8

  5. Time to Change in Hb Concentration ≥1 g/dL

    Efficacy Time to change in Hb concentration ≥1 g/dL. Subjects who showed Hb concentration increase of ≥1 g/dL (from baseline to week 1, 2, 4, and 8). For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.

    Time frame: Baseline, week 1, 2, 4, and 8

  6. Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8

    Efficacy Hb concentration of \>12 g/dL at any time from week 1 to week 8. Results show the number of participants who achieved Hb concentration of \>12 g/dL at any time from week 1 to week 8.

    Time frame: Week 1 to week 8

  7. Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8

    Efficacy Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.

    Time frame: Week 1 to week 8

  8. S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8

    Efficacy Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.

    Time frame: Week 1 to week 8

  9. Change in Hb Concentration From Baseline to Week 1, 2, and 4

    Efficacy Change in Hb concentration from baseline to week 1, 2, and 4.

    Time frame: Baseline, week 1, 2, and 4

  10. Change in S-ferritin From Baseline to Weeks 1, 2, 4, and 8

    Efficacy Changes in s-ferritin from baseline to weeks 1, 2, 4, and 8.

    Time frame: Baseline, week 1, 2, 4, and 8

  11. Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8

    Efficacy Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8.

    Time frame: Baseline, week 1, 2, 4, and 8

  12. Change in Concentration of S-iron From Baseline to Week 1, 2, 4, and 8

    Efficacy Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.

    Time frame: Baseline, week 1, 2, 4, and 8

  13. Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8

    Efficacy Change in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. The Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52. A score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated. Total score was calculated as shown below: Total score= Sum of individual scores x 13 / Number of items answered

    Time frame: Baseline, week 1, 2, and 8

  14. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  15. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  16. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  17. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  18. Health Care Resource Use Questionnaire

    Pharmacoeconomics Resources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).

    Time frame: Baseline

07

Results

Posted Mar 6, 2020

Participant flow

A total of 2560 subjects were screened and 1538 subjects were randomised into the trial.

Participant flow — Overall Study
MilestoneIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Started1027511
Completed971476
Not completed5635
Withdrew: Non-serious ae12
Withdrew: Serious ae73
Withdrew: Withdrawal by subject199
Withdrew: Lost to follow-up137
Withdrew: Physician decision53
Withdrew: Sponsor decision01
Withdrew: Protocol violation02
Withdrew: Death32
Withdrew: Moved, poor venous access, transport64
Withdrew: Not treated22

Outcome measures

PrimaryChange in Hemoglobin (Hb) From Baseline to Week 8

Efficacy Evaluate the effect of iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA). Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with NDD-CKD and IDA, when oral iron preparations were ineffective or could not be used, or in whom the Hb measurement at screening in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.

Time frame:
Baseline to week 8
Reported as:
Least squares mean · g/dL
Change in Hemoglobin (Hb) From Baseline to Week 8
g/dLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Change in Hemoglobin (Hb) From Baseline to Week 81.22 (1.14 to 1.31)1.14 (1.03 to 1.26)
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mean difference (final values): 0.08 · 95% CI -0.06 to 0.23The Mixed Model for Repeated Measurement (MMRM) used for testing, included the fixed, categorical effects of treatment, week, treatment-by-week interaction, strata, and the continuous covariates of baseline Hb and baseline Hb-by-week interaction.
PrimaryIncidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.

Time frame:
Baseline to week 8
Reported as:
Count of participants · Participants
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions30
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose · 95% two-sided ci (iron isomaltoside): 0.3 · 95% CI 0.06 to 0.86
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Risk difference (rd): 0.29 · 95% CI -0.19 to 0.77
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Risk difference (rd): 0.10 · 95% CI -0.57 to 0.48
SecondaryComposite Cardiovascular Adverse Events (AEs)

Safety Results show the composite cardiovascular AEs, that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.

Time frame:
Baseline, week 1, 2, and 8
Reported as:
Count of participants · Participants
Composite Cardiovascular Adverse Events (AEs)
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Composite Cardiovascular Adverse Events (AEs)4235
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Fisher Exact · p = 0.0248
SecondaryTime to First Composite Cardiovascular Safety AE

Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Median · Week
Time to First Composite Cardiovascular Safety AE
WeekIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time to First Composite Cardiovascular Safety AENA (NA to NA)NA (NA to NA)
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Log Rank · p = 0.0185
SecondaryS-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8

Safety Results show the number of participants who had s-phosphate \<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Count of participants · Participants
S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8324
SecondaryHb Concentration Increase of ≥1 g/dL From Baseline to Week 1, 2, 4, and 8

Efficacy Results show Hb responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 1 g/dL from baseline to the week in question was observed (from baseline to week 1, 2, 4, and 8).

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Count of participants · Participants
Hb Concentration Increase of ≥1 g/dL From Baseline to Week 1, 2, 4, and 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Responder YES week 120078
Responder YES week 2339112
Responder YES week 4430174
Responder YES week 8474226
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = 0.0478 · Odds ratio (or): 1.37 · 95% CI 1.00 to 1.87
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = <0.0001 · Odds ratio (or): 1.81 · 95% CI 1.39 to 2.36
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = 0.0048 · Odds ratio (or): 1.41 · 95% CI 1.11 to 1.79
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = 0.9440 · Odds ratio (or): 1.01 · 95% CI 0.80 to 1.27
SecondaryTime to Change in Hb Concentration ≥1 g/dL

Efficacy Time to change in Hb concentration ≥1 g/dL. Subjects who showed Hb concentration increase of ≥1 g/dL (from baseline to week 1, 2, 4, and 8). For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Median · Days
Time to Change in Hb Concentration ≥1 g/dL
DaysIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time to Change in Hb Concentration ≥1 g/dL56 (28 to 56)56 (28 to NA)
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Log Rank · p = 0.0174
SecondaryHb Concentration of >12 g/dL at Any Time From Week 1 to Week 8

Efficacy Hb concentration of \>12 g/dL at any time from week 1 to week 8. Results show the number of participants who achieved Hb concentration of \>12 g/dL at any time from week 1 to week 8.

Time frame:
Week 1 to week 8
Reported as:
Count of participants · Participants
Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8259121
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Regression, Logistic · p = 0.5074 · Odds ratio (or): 1.10 · 95% CI 0.83 to 1.45
SecondaryHb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8

Efficacy Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.

Time frame:
Week 1 to week 8
Reported as:
Count of participants · Participants
Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8307133
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Regression, Logistic · p = 0.1035 · Odds ratio (or): 1.24 · 95% CI 0.96 to 1.60
SecondaryS-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8

Efficacy Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.

Time frame:
Week 1 to week 8
Reported as:
Count of participants · Participants
S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8873388
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Regression, Logistic · p = <0.0001 · Odds ratio (or): 1.82 · 95% CI 1.38 to 2.40
SecondaryChange in Hb Concentration From Baseline to Week 1, 2, and 4

Efficacy Change in Hb concentration from baseline to week 1, 2, and 4.

Time frame:
Baseline, week 1, 2, and 4
Reported as:
Mean · g/dL
Change in Hb Concentration From Baseline to Week 1, 2, and 4
g/dLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 10.44 ± 0.940.21 ± 1.02
Week 20.77 ± 1.160.50 ± 1.15
Week 41.08 ± 1.320.90 ± 1.33
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 0.22 · 95% CI 0.12 to 0.31
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 0.25 · 95% CI 0.14 to 0.36
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0208 · Mean difference (final values): 0.15 · 95% CI 0.02 to 0.28
SecondaryChange in S-ferritin From Baseline to Weeks 1, 2, 4, and 8

Efficacy Changes in s-ferritin from baseline to weeks 1, 2, 4, and 8.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Mean · ng/mL
Change in S-ferritin From Baseline to Weeks 1, 2, 4, and 8
ng/mLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 1492.4 ± 309.7183.9 ± 129.4
Week 2381.2 ± 283.8292.4 ± 210.4
Week 4258.4 ± 214.5255.4 ± 265.6
Week 8191.3 ± 196.1187.9 ± 210.6
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 309.2 · 95% CI 280.7 to 337.8
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 95.8 · 95% CI 67.9 to 123.7
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.7834 · Mean difference (final values): 3.5 · 95% CI -21.2 to 28.1
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.7621 · Mean difference (final values): 3.3 · 95% CI -18.1 to 24.7
SecondaryChange in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8

Efficacy Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Mean · percent
Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8
percentIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 112.10 ± 31.994.31 ± 23.10
Week 25.84 ± 29.795.64 ± 14.35
Week 44.99 ± 30.005.59 ± 12.31
Week 85.10 ± 30.175.93 ± 12.86
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 8.8 · 95% CI 6.9 to 10.7
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0129 · Mean difference (final values): 1.3 · 95% CI 0.3 to 2.4
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.2403 · Mean difference (final values): 0.5 · 95% CI -0.4 to 1.5
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.8094 · Mean difference (final values): 0.1 · 95% CI -0.9 to 1.2
SecondaryChange in Concentration of S-iron From Baseline to Week 1, 2, 4, and 8

Efficacy Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Mean · μg/dL
Change in Concentration of S-iron From Baseline to Week 1, 2, 4, and 8
μg/dLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 134.8 ± 99.711.1 ± 71.1
Week 211.1 ± 90.612.4 ± 44.1
Week 46.5 ± 91.210.2 ± 38.3
Week 87.1 ± 91.312.4 ± 41.9
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 26.5 · 95% CI 20.4 to 32.7
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.2229 · Mean difference (final values): 1.9 · 95% CI -1.2 to 5.1
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.9046 · Mean difference (final values): -0.2 · 95% CI -2.9 to 2.6
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.1307 · Mean difference (final values): -2.5 · 95% CI -5.8 to 0.8
SecondaryChange in Fatigue Symptoms From Baseline to Week 1, 2, and 8

Efficacy Change in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. The Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52. A score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated. Total score was calculated as shown below: Total score= Sum of individual scores x 13 / Number of items answered

Time frame:
Baseline, week 1, 2, and 8
Reported as:
Mean · score on a scale
Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8
score on a scaleIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 15.04 ± 8.855.01 ± 7.93
Week 27.29 ± 9.847.63 ± 9.74
Week 89.13 ± 11.099.07 ± 11.40
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.8196 · Mean difference (final values): 0.10 · 95% CI -0.73 to 0.92
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.7132 · Mean difference (final values): -0.17 · 95% CI -1.06 to 0.73
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.5860 · Mean difference (final values): 0.27 · 95% CI -0.71 to 1.25
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · US dollars ($)
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking
US dollars ($)Iron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Cost of public transport/taxi0.0 (0 to 87)0.0 (0 to 46)
Cost of parking0.0 (0 to 45)0.0 (0 to 25)
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · miles
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car
milesIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car19.0 (0 to 232)18.0 (0 to 240)
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · Hours
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit
HoursIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time spent on visit2.00 (0.0 to 6.3)2.00 (0.0 to 6.0)
Total time spent helping on visit2.00 (0.0 to 6.3)2.00 (0.0 to 10.5)
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Count of participants · Participants
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
In employment, YES15257
Took time off work to attend, YES7026
Assistance by others to attend visit, YES410197
Others took time off work to attend, YES8240
SecondaryHealth Care Resource Use Questionnaire

Pharmacoeconomics Resources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · hours
Health Care Resource Use Questionnaire
hoursIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time spent per site staff1.17 (0.0 to 20.8)1.00 (0.0 to 20.1)
Time spent per subject2.58 (0.5 to 20.8)2.33 (0.2 to 20.3)

Adverse events

Collected over From the time a subjects had signed the informed consent form (CRF) and until they had completed the study, all adverse events (AEs) or serious adverse events (SAEs) were reported in the CRF. The actual study duration was 8 weeks (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 10 weeks (including a 14-day screening period).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iron Isomaltoside/Ferric Derisomaltose3/1,019 (0.3%)83/1,019 (8.1%)56/1,019 (5.5%)
Iron Sucrose3/506 (0.6%)50/506 (9.9%)34/506 (6.7%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Cardiac failure congestiveCardiac disorders7/101911/506
Acute kidney injuryRenal and urinary disorders7/10195/506
Chronic kidney diseaseRenal and urinary disorders5/10193/506
CellulitisInfections and infestations1/10193/506
Chest painGeneral disorders2/10193/506
End stage renal diseaseRenal and urinary disorders5/10192/506
Atrial fibrillationCardiac disorders1/10192/506
Cardiac arrestCardiac disorders1/10192/506
Urinary tract infectionInfections and infestations3/10192/506
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/10192/506
Most frequent other events
Most frequent other events
EventIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Urinary tract infectionInfections and infestations22/101914/506
HypertensionVascular disorders14/101913/506
HyperkalaemiaMetabolism and nutrition disorders22/10199/506

Baseline characteristics

Age, Continuous
Age, Continuous(years)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Mean68.3 ± 12.369.3 ± 12.368.6 ± 12.3
Age, Customized
Age, Customized(participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Between 18 and 65 years337151488
65-84 years608316924
> 84 years8244126
Sex: Female, Male
Sex: Female, Male(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Female633329962
Male394182576
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Hispanic or Latino476248724
Not Hispanic or Latino551263814
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
American Indian or Alaska Native224
Asian161127
Native Hawaiian or Other Pacific Islander101
Black or African American264117381
White7313751106
More than one race202
Unknown or Not Reported11617
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Mexican437
Indigenous Mexican101
Mixed (Caucasian and Native american)101
Hispanic437
Central Indian101
Guyanese101
Other (Mixed: not declared)101
Region of Enrollment
Region of Enrollment(participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
United States10275111538
Current smoker
Current smoker(participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
YES11853171
NO9094581367
08

Study locations

141 sites
  • Pharmacosmos Investigational Site
    Huntsville, Alabama 35805, United States
  • Pharmacosmos Investigational Site
    Little Rock, Arkansas 72204, United States
  • Pharmacosmos Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pharmacosmos Investigational Site
    Chula Vista, California 91910, United States
  • Pharmacosmos Investigational Site
    Fresno, California 93720, United States
  • Pharmacosmos Investigational Site
    Glendale, California 91204, United States
  • Pharmacosmos Investigational Site
    Glendale, California 91206, United States
  • Pharmacosmos Investigational Site
    Granada Hills, California 91344, United States
  • Pharmacosmos Investigational Site
    La Mesa, California 91942, United States
  • Pharmacosmos Investigational Site
    Los Angeles, California 90022, United States
  • Pharmacosmos Investigational Site
    Los Angeles, California 90025, United States
  • Pharmacosmos Investigational Site1
    Los Angeles, California 90048, United States
  • Pharmacosmos Investigational Site2
    Los Angeles, California 90048, United States
  • Pharmacosmos Investigational Site
    Los Angeles, California 90057, United States
  • Pharmacosmos Investigational Site
    Lynwood, California 90262, United States
  • Pharmacosmos Investigational Site
    Montebello, California 90640, United States
  • Pharmacosmos Investigational Site
    Northridge, California 31324, United States
  • Pharmacosmos Investigational Site
    Northridge, California 91324, United States
  • Pharmacosmos Investigational Site
    Porterville, California 93257, United States
  • Pharmacosmos Investigational Site
    Rialto, California 92377, United States
  • Pharmacosmos Investigational Site
    Riverside, California 92505, United States
  • Pharmacosmos Investigational Site
    Sacramento, California 95825, United States
  • Pharmacosmos Investigational Site
    San Dimas, California 91773, United States
  • Pharmacosmos Investigational Site
    San Francisco, California 94110, United States
  • Pharmacosmos Investigational Site
    Tarzana, California 91356, United States
  • Pharmacosmos Investigational Site
    Arvada, Colorado 80002, United States
  • Pharmacosmos Investigational Site
    Denver, Colorado 80218, United States
  • Pharmacosmos Investigational Site
    Westminster, Colorado 80031, United States
  • Pharmacosmos Investigational Site
    Middlebury, Connecticut 06762, United States
  • Pharmacosmos Investigational Site
    Plainville, Connecticut 06062, United States
  • Pharmacosmos Investigational Site
    Boynton Beach, Florida 33426, United States
  • Pharmacosmos Investigational Site
    Brandon, Florida 33511, United States
  • Pharmacosmos Investigational Site
    Coral Gables, Florida 33134, United States
  • Pharmacosmos Investigational Site
    Coral Springs, Florida 33071, United States
  • Pharmacosmos Investigational Site
    Doral, Florida 33166, United States
  • Pharmacosmos Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • Pharmacosmos Investigational Site1
    Hialeah, Florida 33012, United States
  • Pharmacosmos Investigational Site2
    Hialeah, Florida 33012, United States
  • Pharmacosmos Investigational Site3
    Hialeah, Florida 33012, United States
  • Pharmacosmos Investigational Site
    Hollywood, Florida 33024, United States
  • Pharmacosmos Investigational Site
    Homestead, Florida 33030, United States
  • Pharmacosmos Investigational Site
    Lake City, Florida 32024, United States
  • Pharmacosmos Investigational Site1
    Lauderdale Lakes, Florida 33313, United States
  • Pharmacosmos Investigational Site2
    Lauderdale Lakes, Florida 33313, United States
  • Pharmacosmos Investigational Site
    Miami Beach, Florida 33140, United States
  • Pharmacosmos Investigational Site
    Miami Lakes, Florida 33014, United States
  • Pharmacosmos Investigational Site1
    Miami, Florida 33015, United States
  • Pharmacosmos Investigational Site2
    Miami, Florida 33015, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33126, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33133, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33135, United States
  • Pharmacosmos Investigational Site1
    Miami, Florida 33144, United States
  • Pharmacosmos Investigational Site2
    Miami, Florida 33144, United States
  • Pharmacosmos Investigational Site3
    Miami, Florida 33144, United States
  • Pharmacosmos Investigational Site1
    Miami, Florida 33145, United States
  • Pharmacosmos Investigational Site2
    Miami, Florida 33145, United States
  • Pharmacosmos Investigational Site3
    Miami, Florida 33145, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33147, United States
  • Pharmacosmos Investigational Site1
    Miami, Florida 33165, United States
  • Pharmacosmos Investigational Site2
    Miami, Florida 33165, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33172, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33173, United States
  • Pharmacosmos Investigational Site1
    Miami, Florida 33175, United States
  • Pharmacosmos Investigational Site2
    Miami, Florida 33175, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33176, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33183, United States
  • Pharmacosmos Investigational Site1
    Miami, Florida 33186, United States
  • Pharmacosmos Investigational Site2
    Miami, Florida 33186, United States
  • Pharmacosmos Investigational Site
    Naples, Florida 34102, United States
  • Pharmacosmos Investigational Site
    Ocala, Florida 34471, United States
  • Pharmacosmos Investigational Site
    Palmetto Bay, Florida 33157, United States
  • Pharmacosmos Investigational Site
    Pembroke Pines, Florida 33026, United States
  • Pharmacosmos Investigational Site
    Plantation, Florida 33322, United States
  • Pharmacosmos Investigational Site
    Port Charlotte, Florida 33952, United States
  • Pharmacosmos Investigational Site
    Saint Petersburg, Florida 33713, United States
  • Pharmacosmos Investigational Site1
    Tampa, Florida 33607, United States
  • Pharmacosmos Investigational Site2
    Tampa, Florida 33607, United States
  • Pharmacosmos Investigational Site
    Tampa, Florida 33614, United States
  • Pharmacosmos Investigational Site
    W. Miami, Florida 33144, United States
  • Pharmacosmos Investigational Site
    Atlanta, Georgia 30342, United States
  • Pharmacosmos Investigational Site
    Augusta, Georgia 30901, United States
  • Pharmacosmos Investigational Site
    Macon, Georgia 31217, United States
  • Pharmacosmos Investigational Site
    Chicago, Illinois 60611, United States
  • Pharmacosmos Investigational Site
    Chicago, Illinois 60643, United States
  • Pharmacosmos Investigational Site
    Crystal Lake, Illinois 60012, United States
  • Pharmacosmos Investigational Site
    Hinsdale, Illinois 60521, United States
  • Pharmacosmos Investigational Site
    Fort Wayne, Indiana 48604, United States
  • Pharmacosmos Investigational Site
    Marion, Indiana 46952, United States
  • Pharmacosmos Investigational Site
    Merrillville, Indiana 46410, United States
  • Pharmacosmos Investigational Site
    Michigan City, Indiana 46360, United States
  • Pharmacosmos Investigational Site
    Kansas City, Kansas 66160, United States
  • Pharmacosmos Investigational Site
    Wichita, Kansas 67214, United States
  • Pharmacosmos Investigational Site
    Owensboro, Kentucky 42301, United States
  • Pharmacosmos Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Pharmacosmos Investigational Site
    Covington, Louisiana 70433, United States
  • Pharmacosmos Investigational Site
    Shreveport, Louisiana 71101, United States
  • Pharmacosmos Investigational Site
    Annapolis, Maryland 21401, United States
  • Pharmacosmos Investigational Site
    Bethesda, Maryland 20817, United States
  • Pharmacosmos Investigational Site
    Rockville, Maryland 20852, United States
  • Pharmacosmos Investigational Site
    Grand Rapids, Michigan 49525, United States

Showing the first 100 of 141 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sunil Bhandari, Lars Lykke Thomsen. Single 1000 mg infusion of iron isomaltoside1000 single 1000 mg infusion of iron isomaltoside 1000 demonstrates a more rapid hemoglobin response and reduced risk of cardiovascular adverse events compared to multiple dose iron sucrose In patients with iron deficiency anemia and nondialysis-dependent CKD. Nephrology Dialysis Transplantation 34 (Supplement 1): i349-i350, 2019, https://academic.oup.com/ndt/article/34/Supplement_1/gfz101.SaO035/5515662
  • Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021 Jan 1;36(1):111-120. doi: 10.1093/ndt/gfaa011. PubMed 32049331 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in May 2018, 18 months.

Results were first posted in Mar 2020, 1 year 9 months after primary completion. A results delay was requested in May 2019.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Oct 21, 2016
StartActual
Nov 29, 2016
Primary completionActual
May 29, 2018
CompletionActual
May 29, 2018
Results delay requested
May 7, 2019
Results first posted
Mar 6, 2020
Last update
Oct 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02940860
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Oct 21, 2016
Start date
Nov 29, 2016
Primary completion
May 29, 2018
Completion
May 29, 2018
Results posted
Mar 6, 2020
Last update
Oct 6, 2020

Study contacts

Pharmacosmos A/S Clinical and Non-clinical Research
study director · Pharmacosmos A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion